Oncocyte Enters $2B Market With Transplant Rejection Monitoring Test

• Oncocyte Corporation (NASDAQ: OCX) completed the development and clinical validation of the Laboratory Test for its newly-branded VitaGraft Transplant Monitoring tests for Liver and Kidney, entering a $2 billion US market.

• The company also opened an Early Adopter Program (EAP), giving access to transplant centers before a potential CMS coverage decision and full commercial launch.

• VitaGraft has been well-studied across Kidney, Liver, and Heart with over 20 peer-reviewed publications from studies in over 600 patients and over 5,000 samples.

• It is a simple and non-invasive blood test that has been shown to accurately rule-out rejection or injury following transplant with negative predictive values above 97%, helping avoid around 30% of unnecessary biopsies.

• Furthermore, the test can assist physicians in optimizing the dosing of immunosuppressive drugs to minimize drug-related side effects and toxicity.

• Price Action: OCX shares are up 1.20% at $0.87 during the market session on the last check Wednesday.

See more from Benzinga

• Sanofi Offloads 17 Products To Neuraxpharm

• HUTCHMED Highlights SAVANNAH Trial Data Of Savolitinib Combo In Lung Cancer Setting

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.